Arctic Bioscience (Norway) Performance
| ABS Stock | NOK 1.94 0.05 2.51% |
The firm shows a Beta (market volatility) of 0.47, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arctic Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Arctic Bioscience is expected to be smaller as well. At this point, Arctic Bioscience has a negative expected return of -1.56%. Please make sure to confirm Arctic Bioscience's maximum drawdown, rate of daily change, and the relationship between the jensen alpha and kurtosis , to decide if Arctic Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Arctic Bioscience AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 12.6 M | |
| Total Cashflows From Investing Activities | -36.5 M | |
| Free Cash Flow | -76 M |
Arctic |
Arctic Bioscience Relative Risk vs. Return Landscape
If you would invest 1,500 in Arctic Bioscience AS on September 3, 2024 and sell it today you would lose (1,306) from holding Arctic Bioscience AS or give up 87.07% of portfolio value over 90 days. Arctic Bioscience AS is producing return of less than zero assuming 14.0481% volatility of returns over the 90 days investment horizon. Simply put, majority of traded equity instruments are less risky than Arctic on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Arctic Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arctic Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arctic Bioscience AS, and traders can use it to determine the average amount a Arctic Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1114
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABS |
Estimated Market Risk
| 14.05 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.56 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arctic Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arctic Bioscience by adding Arctic Bioscience to a well-diversified portfolio.
Arctic Bioscience Fundamentals Growth
Arctic Stock prices reflect investors' perceptions of the future prospects and financial health of Arctic Bioscience, and Arctic Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arctic Stock performance.
| Return On Equity | -0.22 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (1.98) % | |||
| Operating Margin | (1.86) % | |||
| Current Valuation | 145.21 M | |||
| Shares Outstanding | 24.38 M | |||
| Price To Book | 1.05 X | |||
| Price To Sales | 14.73 X | |||
| Revenue | 21.52 M | |||
| EBITDA | (39.72 M) | |||
| Book Value Per Share | 13.19 X | |||
| Cash Flow From Operations | (39.49 M) | |||
| Earnings Per Share | (1.75) X | |||
| Total Asset | 341.47 M | |||
About Arctic Bioscience Performance
By examining Arctic Bioscience's fundamental ratios, stakeholders can obtain critical insights into Arctic Bioscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Arctic Bioscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Arctic Bioscience AS, a biotechnology company, provides nutraceutical and pharmaceutical products. Arctic Bioscience AS was incorporated in 2011 and is based in rsta, Norway. ARCTIC BIOSCIENCE is traded on Oslo Stock Exchange in Norway.Things to note about Arctic Bioscience performance evaluation
Checking the ongoing alerts about Arctic Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arctic Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arctic Bioscience generated a negative expected return over the last 90 days | |
| Arctic Bioscience has high historical volatility and very poor performance | |
| Arctic Bioscience may become a speculative penny stock | |
| Arctic Bioscience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 21.52 M. Net Loss for the year was (42.58 M) with profit before overhead, payroll, taxes, and interest of 5.8 M. | |
| Arctic Bioscience generates negative cash flow from operations | |
| About 55.0% of the company shares are held by company insiders |
- Analyzing Arctic Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arctic Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Arctic Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arctic Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arctic Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arctic Bioscience's stock. These opinions can provide insight into Arctic Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Arctic Stock
Arctic Bioscience financial ratios help investors to determine whether Arctic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arctic with respect to the benefits of owning Arctic Bioscience security.